A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis

Peng, Qinglin; Zhang, Yamei; Liang, Lin; Liu, Xia; Ye, Lifang; Yang, Hanbo; Lu, Zhigang; Shu, Xi; Lu, Xin; Wang, Guochun

doi:10.1111/cei.13404

Cited by 31 publications

(32 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated serum neopterin patients have more active disease—higher DAS and lower CMAS—consistent with prior studies [ 19 ]. Although reports from Japan and China document anti-MDA5 (anti-CADM140) dermatomyositis to have the most elevated serum neopterin level, especially in patients with severe lung disease [ 26 , 27 ], there was not a statistically significant difference in neopterin level between the different MSAs in our cohort. This discrepancy is severely influenced by the fact that we have a small number of MDA5 positive patients in our study (only two patients have MDA5 antibody) and that interstitial lung disease is also associated with an increased neopterin [ 28 ].…”

Section: Discussioncontrasting

confidence: 71%

Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers

2021

View full text Add to dashboard Cite

Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomyositis (JDM). The goal of this retrospective study is to define immunological and clinical differences between untreated JDM patients with either normal or elevated (>10 mmol/L) levels of neopterin, a biomarker of macrophage activation. We included all JDM with neopterin data obtained before initiating medical therapy. We assessed T, B, NK cell populations, muscle enzymes, and disease activity scores for skin (sDAS), muscle (mDAS), total (tDAS), the duration of untreated disease, disease course, and myositis-specific antibody (MSA). Seventy-nine percent of 139 untreated JDM patients had elevated serum neopterin. The group with elevated neopterin had significantly more active disease: tDAS 11.9 vs. 8.1 (p < 0.0001), mDAS 5.8 vs. 3.1 (p < 0.0001), sDAS 6.1 vs. 4.9 (p = 0.0002), aldolase 24.0 vs. 7.6 U/L (p < 0.0001), von Willebrand factor antigen (p < 0.0001), and ESR 19.8 vs. 11.5 mm/hr (p = 0.01). The flow cytometry documented both reduced T cells (1494 vs. 2278/mm3, p = 0.008) and NK cells (145 vs. 240/mm3, p = 0.003). TNFα-308AA/AG polymorphism was more common in children with elevated neopterin than TNFα-308GG (p 0.05). We conclude that the availability of neopterin data will contribute to the rapid assessment of untreated JDM disease activity.

show abstract

Section: Discussioncontrasting

confidence: 71%

Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers

2021

View full text Add to dashboard Cite

show abstract

“…Hence, increased NPT levels are often detected in OS-related diseases, and it is reported that NPT may be an indirect indicator of OS induced by the immune system (Murr et al, 2002). Moreover, NPT is associated with the severity of disease and is considered a potential biomarker predicting adverse outcomes in numerous diseases (Peng et al, 2020). In our study, a significant elevation of serum levels of NPT has been shown in she-camels with CE.…”

Section: Discussionsupporting

confidence: 61%

Oxidative stress, ceruloplasmin and neopterin biomarkers in dromedary camels with clinical endometritis

et al. 2022

View full text Add to dashboard Cite

The purpose of this study is to investigate the role of some oxidative stress (OS), ceruloplasmin (Cp), and neopterin (NPT) as diagnostic biomarkers for dromedary camels endometritis as well as to explore the impact of ceftiofur treatment on endometritis. Camels were categorized into two groups; healthy control group (n = 20) and endometritis group (n = 60). She-camels with clinical signs of endometritis (CE) received 6.6 mg/kg BW of ceftiofur (i/m). On days 7, and 14, she-camels were evaluated and clinical cure or failure to cure was determined. The comparison of the groups for OS demonstrated that endometritis caused an increase in serum malondialdehyde (sMDA), Cp, and NPT levels (P<0.05), but decreased serum levels of superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) (P<0.05). The most prevalent pathogens involved in the etiology of CE are Arcanobacterium pyogenes, Streptococcus pyogenes, and Staphylococcus aureus. All examined biomarkers demonstrated a high degree of recognition between CE camel and healthy controls (the area under the curve (AUC) was 95.9 for NPT). A higher proportion of camels with CE that were treated with ceftiofur (90%, P<0.0001) showed clinical cure by the first dose, while 10% required a second dose. In conclusion, CE causes increased oxidative reactions and decreased antioxidant defense competence. Subsequently, the alteration in that balance that was represented by the biomarkers of OS could be beneficial for clinical practice and basic clinical research. Additionally, all trials demonstrated the efficacy of ceftiofur for the treatment of CE in she-camel.

show abstract

“…Neopterin levels, another marker of macrophage activation, are elevated in DM patients with anti-MDA5 Abs in association with RP-ILD and reduced survival. A positive correlation of neopterin levels with ferritin and markers of disease severity, and a negative correlation with pulmonary function have been demonstrated ( 115 ). Multiple chemokines can induce the recruitment of M2 macrophages.…”

Section: Pathogenesis Of the Diseasementioning

confidence: 99%

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies

2021

View full text Add to dashboard Cite

Anti-MDA5 dermatomyositis is a rare systemic autoimmune disease, historically described in Japanese patients with clinically amyopathic dermatomyositis and life-threatening rapidly progressive interstitial lung disease. Subsequently, the complete clinical spectrum of the disease was enriched by skin, articular and vascular manifestations. Depending on the predominance of these symptoms, three distinct clinical phenotypes with different prognosis are now defined. To date, the only known molecular component shared by the three entities are specific antibodies targeting MDA5, a cytosolic protein essential for antiviral host immune responses. Several biological tools have emerged to detect these antibodies, with drawbacks and limitations for each of them. However, the identification of this highly specific serological marker of the disease raises the question of its role in the pathogenesis. Although current knowledge on the pathogenic mechanisms that take place in the disease are still in their enfancy, several lines of evidence support a central role of interferon-mediated vasculopathy in the development of skin and lung lesions, as well as a possible pathogenic involvement of anti-MDA5 antibodies. Here, we review the clinical and biological evidences in favor of these hypothesis, and we discuss the contribution of emerging therapies that shed some light on the pathogenesis of the disease.

show abstract

A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis

Cited by 31 publications

References 43 publications

Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers

Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers

Oxidative stress, ceruloplasmin and neopterin biomarkers in dromedary camels with clinical endometritis

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies

Contact Info

Product

Resources

About